<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="rmv2113-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 2</label>
 <caption>
  <p>Major drugs in clinical development for treatment of COVID‐19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Drug</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Mechanism</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Dosage and mode of administration</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Side effects</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Clinical trial</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Lopinavir/ritonavir</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g005.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Protease inhibitors, that work together to block the viral replication</td>
    <td align="left" valign="top" rowspan="1" colspan="1">400 mg/100 mg, 2 times/d (Oral)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0007">
      <list-item id="rmv2113-li-0041">
       <p>Hypersensitivity reaction,</p>
      </list-item>
      <list-item id="rmv2113-li-0042">
       <p>Pancreatitis,</p>
      </list-item>
      <list-item id="rmv2113-li-0043">
       <p>Angioedema,</p>
      </list-item>
      <list-item id="rmv2113-li-0044">
       <p>Toxic epidermal necrolysis,</p>
      </list-item>
      <list-item id="rmv2113-li-0045">
       <p>AV block,</p>
      </list-item>
      <list-item id="rmv2113-li-0046">
       <p>Renal failure</p>
      </list-item>
      <list-item id="rmv2113-li-0047">
       <p>Hyperglycaemia,</p>
      </list-item>
      <list-item id="rmv2113-li-0048">
       <p>Leukopenia,</p>
      </list-item>
      <list-item id="rmv2113-li-0049">
       <p>Hypertriglyceridemia,</p>
      </list-item>
      <list-item id="rmv2113-li-0050">
       <p>Neutropenia,</p>
      </list-item>
      <list-item id="rmv2113-li-0051">
       <p>Hepatotoxicity etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">11 trials (for instance NCT04307693, 3/13/20)</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Remdesivir</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g006.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Gets incorporated into viral RNA leading to RNA termination trouble and inhibition of viral replication.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">200 mg once for first day, followed by 100 mg/d (Intravenous)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0008">
      <list-item id="rmv2113-li-0052">
       <p>Elevated liver enzymes,</p>
      </list-item>
      <list-item id="rmv2113-li-0053">
       <p>Nausea,</p>
      </list-item>
      <list-item id="rmv2113-li-0054">
       <p>Rectal bleeding,</p>
      </list-item>
      <list-item id="rmv2113-li-0055">
       <p>Vomiting etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">6 trials (eg, NCT04292899, 3/19/20)</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Favipiravir</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g007.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase inhibitor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">1600 mg twice for 1 day followed by 600 mg 2 times/d (Oral)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0009">
      <list-item id="rmv2113-li-0056">
       <p>Neurological and psychiatric symptoms,</p>
      </list-item>
      <list-item id="rmv2113-li-0057">
       <p>Anaphylaxis,</p>
      </list-item>
      <list-item id="rmv2113-li-0058">
       <p>Hepatic dysfunction,</p>
      </list-item>
      <list-item id="rmv2113-li-0059">
       <p>Acute kidney injury,</p>
      </list-item>
      <list-item id="rmv2113-li-0060">
       <p>Toxic Epidermal Necrolysis (TEN),</p>
      </list-item>
      <list-item id="rmv2113-li-0061">
       <p>Colitis haemorrhage etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Atleast three trials (eg, NCT04303299</p>
     <p>3/12/2020)</p>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Chloroquine</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g008.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Interferes with the cellular receptor ACE2 and also impairs the acidification of endosomes, thereby impeding the virus trafficking inside the cells</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>500 mg (300 mg for chloroquine) for 2 times/d</p>
     <p>(Oral)</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0010">
      <list-item id="rmv2113-li-0062">
       <p>Anaphylaxis or anaphylactoid reaction,</p>
      </list-item>
      <list-item id="rmv2113-li-0063">
       <p>Neuropsychiatric disorders,</p>
      </list-item>
      <list-item id="rmv2113-li-0064">
       <p>Neuromuscular impairment,</p>
      </list-item>
      <list-item id="rmv2113-li-0065">
       <p>Hepatitis thrombocytopenia,</p>
      </list-item>
      <list-item id="rmv2113-li-0066">
       <p>Pancytopenia,</p>
      </list-item>
      <list-item id="rmv2113-li-0067">
       <p>Neutropenia,</p>
      </list-item>
      <list-item id="rmv2113-li-0068">
       <p>aplastic anaemia etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">At least ten trials (eg, NCT04303507, 3/11/20; NCT04261517, 2/14/20)</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Ribavirin</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g009.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Nucleoside analog of ribofuranose that inhibits viral RNA synthesis</td>
    <td align="left" valign="top" rowspan="1" colspan="1">500 mg for 2‐3 times/d in combination with lopinavir/ritonavir or IFN‐α (Intravenous)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0011">
      <list-item id="rmv2113-li-0069">
       <p>Cardiac arrest,</p>
      </list-item>
      <list-item id="rmv2113-li-0070">
       <p>Pulmonary function deterioration,</p>
      </list-item>
      <list-item id="rmv2113-li-0071">
       <p>Headache,</p>
      </list-item>
      <list-item id="rmv2113-li-0072">
       <p>Fatigue,</p>
      </list-item>
      <list-item id="rmv2113-li-0073">
       <p>Abdominal cramps,</p>
      </list-item>
      <list-item id="rmv2113-li-0074">
       <p>Chronic obstructive lung disease,</p>
      </list-item>
      <list-item id="rmv2113-li-0075">
       <p>Chest soreness,</p>
      </list-item>
      <list-item id="rmv2113-li-0076">
       <p>Ventilator dependence,</p>
      </list-item>
      <list-item id="rmv2113-li-0077">
       <p>Conjunctivitis etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">At least 5 trials (NCT04254874, 2/5/20; ChiCTR2000029308, 1/23/20)</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Oseltamavir</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g010.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Neuraminidase inhibitor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">12.5 mL of oral suspension or 75 mg capsule 2 times/d (Oral)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0012">
      <list-item id="rmv2113-li-0078">
       <p>Vomiting,</p>
      </list-item>
      <list-item id="rmv2113-li-0079">
       <p>Nausea,</p>
      </list-item>
      <list-item id="rmv2113-li-0080">
       <p>Headache,</p>
      </list-item>
      <list-item id="rmv2113-li-0081">
       <p>Mood or mental changes,</p>
      </list-item>
      <list-item id="rmv2113-li-0082">
       <p>Skin rashes,</p>
      </list-item>
      <list-item id="rmv2113-li-0083">
       <p>Pain etc.</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">One trial (NCT04261270, 2/7/20)</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>Arbidol</p>
     <p>
      <inline-graphic xlink:href="RMV-9999-e2113-g011.jpg" xlink:title="image" xmlns:xlink="http://www.w3.org/1999/xlink"/>
     </p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Blocks viral fusion</td>
    <td align="left" valign="top" rowspan="1" colspan="1">200 mg for 3 times/d (Oral)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <list list-type="bullet" id="rmv2113-list-0013">
      <list-item id="rmv2113-li-0084">
       <p>Diarrhoea,</p>
      </list-item>
      <list-item id="rmv2113-li-0085">
       <p>Nausea,</p>
      </list-item>
      <list-item id="rmv2113-li-0086">
       <p>Dizziness,</p>
      </list-item>
      <list-item id="rmv2113-li-0087">
       <p>Elevated serum transaminase</p>
      </list-item>
     </list>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Two trials (NCT04260594,2/7/20; NCT04286503, 2/27/20)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
